Refine by
In Vivo Model Suppliers & Manufacturers
44 companies found
based inDijon, FRANCE
Oncodesign is a biopharmaceutical company that offers you powerful technologies and tools to guide you through the development of your drug, from medicinal chemistry to drug candidate. Our therapeutic areas are expanding. In addition to oncology, ...
Select the best drug candidates and their biomarkers using our expertise in pharmacology! The PREDICT® technology module is a centralized manifestation of the key scientific competence of our Experimentation activity. This module is the result ...
based inSeattle, WASHINGTON (USA)
Aptevo Therapeutics is a biotech company focused on bringing novel immuno-oncology therapeutics to market. We leverage the innovative ADAPTIR™ and ADAPTIR-FLEX platform technologies to create therapeutic candidates designed to improve outcomes for ...
ALG.APV-527 is a bispecific antibody candidate targeting 4-1BB x 5T4 and is intended for tumor-directed treatment of solid cancers. It was built using Aptevo’s ADAPTIR™ bispecific technology platform and combines binding domains sourced ...
based inDiepenbeek, BELGIUM
Founded in 2012, InnoSer is an innovative and dynamic contract research organization supporting preclinical development of drugs from its facilities in Belgium and the Netherlands. InnoSer supports its customers in the critical steps of their drug ...
We have specialized facilities for in vitro and in vivo offerings. Our established scientific experience and customized, collaborative approach make InnoSer the ideal ally for your company to achieve meaningful, high-quality and fast results. ...
based inBoston, MASSACHUSETTS (USA)
At Emulate, we understand that animal studies and reductionist models are limited because they are not based on integrated human biology. By leveraging 21st century technologies, we are able to overcome these limitations with living human in vitro ...
Study drug absorption and drug-drug interactions in a primary organoid-based model of the human small ...
based inAbingdon, UNITED KINGDOM
Founded on innovation and operating with an entrepreneurial flair, Oxford Optronix is a global pioneer in design, development and manufacture of sophisticated instrumentation for the life sciences. Our products are designed, developed and ...
Our single-channel laser-Doppler tissue blood flow monitor/perfusion monitoring: Uncompromised reliability in continuous tissue blood flow assessment; Ideally suited to measurements of changing tissue blood flow in acute experimental ...
based inMenlo Park, CALIFORNIA (USA)
Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet has developed a proprietary cell platform process to activate, engineer and ...
Gamma delta T cells represent a new generation of universal cell therapy. The current engineered autologous alpha beta T cell products have shown significant efficacy in hematological malignancies; however comparable efficacy in solid tumors is yet ...
based inBasel, SWITZERLAND
We at Auris Medical are a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. We are focusing on the development of intranasal betahistine ...
The OligoPhore™ / SemaPhore™ technology has been extensively and successfully tested with various siRNA and mRNA sequences in numerous disease models in mice. For the development of our first proprietary drug product, AM-401 ...
based inShanghai, CHINA
Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide. Elpiscience has a robust pipeline of globally innovative cancer immunotherapies covering a wide ...
ES014 is a first-in-class anti-CD39xTGF-β bispecific antibody (bsAb) that simultaneously targets the adenosine and TGF-β pathways, two major immunosuppressive mechanisms in the tumor microenvironment (TME). Solid tumors frequently express ...
based inNeedham, MASSACHUSETTS (USA)
Invicro is an integral part of the REALM IDx, Inc. group, which aims to accelerate personalized medicine, discover novel therapeutic targets and develop innovative therapeutic technologies for unmet medical needs. As a global research partner to the ...
Radiopharmaceutical therapies represent an effective way to treat solid cancers by using tumor targeting small molecules, peptides or biologics to deliver a cytotoxic payload that induces DNA damage in tumor cells, while limiting damage to normal ...
based inSan Diego, CALIFORNIA (USA)
Everyone at AnaBios shares a passion and commitment to make a difference in the development of promising new therapies and cures for patients by reducing the time and expense needed to bring these medicines to patients. We do this by generating ...
based inBoston, MASSACHUSETTS (USA)
Accelerating Discovery in CNS, Cardiometabolic and Inflammatory Disease. We support our clients to achieve more in their target & biomarker programs. Our expertise, curated & disease enriched clinco-omic cohorts, tools and applications for insight ...
We are developing novel causal artificial intelligence and machine learning (AI/ML) and unconventional computing strategies to better understand human biology – and then apply these to deliver better medicine and improve health for people ...
based inCarlsbad, CALIFORNIA (USA)
Qualigen is a biotechnology company focused on the development of novel therapeutic products for the treatment of cancer and infectious diseases, as well as expansion of its flagship FastPack diagnostic platform. The FastPack line of FDA-cleared and ...
Qualigen licensed the G4 selective transcription inhibitor platform from University College London (UCL) in 2022. The licensed technology comprises lead compound QN-302 (formerly SOP1812) and back-up compounds that target regulatory regions of ...
based inToronto, ONTARIO (CANADA)
Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in people with diabetes. This pre-clinical technology is directed at regulating a hormone in the pancreas called somatostatin which in Type ...
Zucara Therapeutics is developing ZT-01, a first-in-class, once-daily therapeutic to prevent insulin-induced hypoglycemia in patients using insulin therapy. ZT-01 is designed to inhibit somatostatin, a pancreatic hormone that impairs the glucagon ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
Bispecific T cell engaging receptors (TCER®) are off-the-shelf biologics that leverage the body’s immune system by redirecting and activating T cells towards cancer cells expressing specific tumor targets. The design of these novel ...
based inLondon, UNITED KINGDOM
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group is pursuing therapeutic projects in orphan diseases, ...
based inBarcelona, SPAIN
Cytes Biotechnologies is a biotechnological company that offers products and services (CRO) based on tissue procurement, cell isolation and cell solutions for in vitro models addressed to the research community worldwide. The company’s main focus ...
based inCambridge, UNITED KINGDOM
CN Bio is a leading bioengineering company specialising in single and multi-organ microphysiological systems and innovative lab technologies. We aim to provide systems that generate clinically translatable data that can enhance the development of ...
Generate human-specific pre-clinical safety and efficacy data with pioneering PhysioMimix single- and multi-organ-on-a-chip ...
based inAudubon, PENNSYLVANIA (USA)
Globus Medical is a leading medical device manufacturer with the goal of improving the quality of life for patients with musculoskeletal disorders. We are inspired by the needs of these patients and by the surgeons and healthcare providers who treat ...
based inBrighton, UNITED KINGDOM
Destiny Pharma is a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention. We have two exciting late-stage clinical assets and a range of earlier research programmes. Our ...
There are two XF-73 dermal programmes in development. One is being run by our China partner and shareholder – China Medical Systems Holdings Limited (CMS) – focused on superficial skin infections and the other is an in-house programme ...
based inLa Tronche, FRANCE
INOVOTION is a Contract Research Laboratory implementing a unique approach to in vivo evaluation for anticancer drug discovery. Our cutting-edge proprietary technology provides early analysis of your compounds before the classical preclinical stage. ...
INOVOTION has developed a unique, highly sensitive and reproducible assay. It is applicable to all preclinical oncology and immuno-oncology drug discovery programs, and monitors the growth and metastatic dissemination of human tumor ...